263 related articles for article (PubMed ID: 31434020)
1. Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.
Del Solar V; Contel M
J Inorg Biochem; 2019 Oct; 199():110780. PubMed ID: 31434020
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
3. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
[TBL] [Abstract][Full Text] [Related]
4. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
5. APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective
Staudacher AH; Li Y; Liapis V; Hou JJC; Chin D; Dolezal O; Adams TE; van Berkel PH; Brown MP
Mol Cancer Ther; 2019 Feb; 18(2):335-345. PubMed ID: 30413648
[TBL] [Abstract][Full Text] [Related]
6. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates.
Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM
Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823
[TBL] [Abstract][Full Text] [Related]
7. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
Fatima SW; Khare SK
J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
[TBL] [Abstract][Full Text] [Related]
8. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
9. Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody-Drug Conjugates Revealing Key Insights into Structure-Activity Relationships.
Steele AD; Kiefer AF; Hwang D; Yang D; Teijaro CN; Adhikari A; Rader C; Shen B
J Med Chem; 2023 Jan; 66(2):1562-1573. PubMed ID: 36599039
[TBL] [Abstract][Full Text] [Related]
10. Site-Specific Antibody Drug Conjugates Using Streamlined Expressed Protein Ligation.
Frutos S; Hernández JL; Otero A; Calvis C; Adan J; Mitjans F; Vila-Perelló M
Bioconjug Chem; 2018 Nov; 29(11):3503-3508. PubMed ID: 30346741
[TBL] [Abstract][Full Text] [Related]
11. Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs).
Yao H; Jiang F; Lu A; Zhang G
Int J Mol Sci; 2016 Feb; 17(2):. PubMed ID: 26848651
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates.
Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L
Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390
[TBL] [Abstract][Full Text] [Related]
13. Immunoconjugates for Cancer Targeting: A Review of Antibody-Drug Conjugates and Antibody-Functionalized Nanoparticles.
Petrilli R; Pinheiro DP; de Cássia Evangelista de Oliveira F; Galvão GF; Marques LGA; Lopez RFV; Pessoa C; Eloy JO
Curr Med Chem; 2021; 28(13):2485-2520. PubMed ID: 32484100
[TBL] [Abstract][Full Text] [Related]
14. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
Ducry L; Stump B
Bioconjug Chem; 2010 Jan; 21(1):5-13. PubMed ID: 19769391
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
Papachristos A; Pippa N; Demetzos C; Sivolapenko G
Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
[TBL] [Abstract][Full Text] [Related]
20. Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy.
Chowdari NS; Pan C; Rao C; Langley DR; Sivaprakasam P; Sufi B; Derwin D; Wang Y; Kwok E; Passmore D; Rangan VS; Deshpande S; Cardarelli P; Vite G; Gangwar S
Bioorg Med Chem Lett; 2019 Feb; 29(3):466-470. PubMed ID: 30579797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
